FGFR3 Protein Overexpression Predicts Bladder Cancer Recurrence, Study Finds

Bladder cancer remains one of the most common malignancies worldwide, and few of its subtypes are as clinically frustrating as high-grade T1 (HGT1) tumors. These cancers have invaded the connective tissue beneath the bladder lining but have not yet reached the muscle wall, placing them in an ambiguous zone between easily managed superficial disease and life-threatening muscle-invasive cancer. Some patients do well for years with bladder-sparing treatment, while others recur rapidly or progress to muscle-invasive disease despite aggressive therapy. A new study published in the Journal of Translational Medicine by a team at Hospital Clínic de Barcelona suggests that part of the answer to this unpredictability may lie in how clinicians measure a single, well-known cancer gene: FGFR3, the fibroblast growth factor receptor 3.

FGFR3 has long occupied a peculiar position in bladder cancer biology. Activating mutations in the gene are among the most frequent genetic alterations in non-muscle invasive bladder cancer, and for years they were generally associated with more favorable outcomes, lower stage, and lower grade disease. Yet the picture in HGT1 tumors has been far murkier. Studies attempting to link FGFR3 mutation status to recurrence or progression in this specific patient group have produced conflicting results, and the gene’s true prognostic value has remained a matter of debate. The Barcelona team, led by Claudia Mercader and senior authors Antoni Vilaseca and Lourdes Mengual, hypothesized that the controversy itself might be the clue: perhaps FGFR3’s role could only be understood if researchers stopped looking at the gene through a single lens and instead examined it at multiple molecular levels simultaneously.

That is precisely what the new study did. The researchers retrospectively analyzed 87 patients treated for primary HGT1 bladder tumors, assessing FGFR3 through three distinct and complementary measurements. First, they determined mutational status using Sanger sequencing, the classic method of reading the gene’s DNA code directly from tumor tissue. Second, they quantified gene expression using reverse transcription-quantitative polymerase chain reaction, or RT-qPCR, a technique that measures how actively the FGFR3 gene is being transcribed into messenger RNA. Third, they evaluated protein expression by immunohistochemistry, a staining method that reveals how much FGFR3 receptor protein accumulates in the tumor cells themselves. This three-tiered approach allowed the team to ask whether DNA mutations, RNA transcription, and protein abundance each carried independent prognostic information.

The molecular findings were striking in themselves. FGFR3 mutations were detected in 33 of the 87 tumors, or 38 percent of the cohort, while protein overexpression was observed in 31 cases, or 36 percent. Critically, the two were strongly linked: tumors carrying FGFR3 mutations were far more likely to overproduce the receptor protein, with an odds ratio of 6 and a confidence interval of 2.35 to 16.3, a relationship that was highly statistically significant. Gene expression measured by RT-qPCR added a third layer, and the concordance and discordance among these three measures across individual tumors provided the researchers with a unique opportunity to disentangle which molecular feature actually mattered for patient outcomes.

To connect these molecular profiles to clinical reality, the team tracked two endpoints that define the HGT1 dilemma: recurrence-free survival, the time before the tumor comes back anywhere in the bladder, and progression-free survival, the time before the disease advances to muscle-invasive or metastatic stages. Survival curves were estimated using the Kaplan-Meier method, and differences between molecular subgroups were tested with the log-rank test. In these univariate analyses, a fascinating divergence emerged. FGFR3 protein overexpression was associated with worse recurrence-free survival, meaning patients whose tumors accumulated high levels of the receptor protein saw their cancers return sooner. Meanwhile, the opposite pattern appeared for progression: FGFR3 mutations and high gene expression were both associated with improved progression-free survival, suggesting that at the DNA and RNA levels, FGFR3 activity might mark a biologically less aggressive form of the disease.

The most consequential result, however, came from the multivariate analysis. Because HGT1 tumors are stratified into risk groups by the European Association of Urology based on factors such as tumor size, number, presence of carcinoma in situ, and recurrence history, the researchers constructed Cox proportional hazards regression models adjusted for this established risk classification. After accounting for these clinical variables, only one molecular measure retained independent prognostic power: FGFR3 protein overexpression, which was associated with worse recurrence-free survival with a hazard ratio of 1.98 and a confidence interval of 1.08 to 3.63. In practical terms, patients whose tumors overexpressed the FGFR3 protein had nearly double the hazard of recurrence compared with those whose tumors did not, regardless of their formal risk group.

This dissociation between the three molecular layers is the study’s most intellectually provocative contribution. A mutation in the FGFR3 gene is a fixed DNA-level event, but whether that mutation translates into runaway receptor production depends on transcriptional regulation, mRNA stability, and protein turnover. The Barcelona data suggest that these layers can carry opposite prognostic signals: mutation and gene overexpression correlated with protection against progression, while protein accumulation signaled heightened recurrence risk. If confirmed, this would mean that the long-standing controversy over FGFR3’s prognostic value in HGT1 disease may stem not from flawed studies but from the fact that different studies measured different things. A gene cannot be summarized by its mutation status alone, and the protein, the ultimate functional output of the genome, may be the most clinically informative readout for recurrence.

The therapeutic implications are equally significant. FGFR3 has become a major drug target in urothelial carcinoma, with FGFR inhibitors such as erdafitinib approved for metastatic disease harboring FGFR alterations, and FGFR-directed antibody-drug conjugates under active investigation. Most of this drug development has focused on muscle-invasive and metastatic settings, where FGFR mutations are less common but still actionable. If protein overexpression proves to be a robust marker of recurrence risk in HGT1 patients, it could help identify which individuals with high-grade T1 tumors might benefit from intensified intravesical therapy, closer surveillance, or earlier consideration of radical cystectomy, while sparing others unnecessary intervention. It could also open the door to trials of FGFR-targeted agents earlier in the disease course, in the bladder-sparing window where the stakes of recurrence and progression are highest.

The authors are careful to frame their conclusions appropriately. This was a retrospective, single-center cohort of 87 patients, and the associations reported are exploratory rather than practice-changing. The team explicitly states that the findings support further evaluation of integrated FGFR3 profiling in larger, independently validated cohorts before any routine clinical implementation. Retrospective designs carry inherent limitations, including selection effects and the possibility of confounding by unmeasured clinical variables, and a cohort of this size cannot exclude modest effects or subgroup heterogeneity. The multivariate adjustment for European Association of Urology risk groups strengthens the analysis, but external validation in multi-institutional cohorts remains the essential next step.

Even with those caveats, the study offers a compelling template for how molecular prognostication in bladder cancer should evolve. Rather than asking whether FGFR3 is good or bad for the patient, the Barcelona team asked which molecular dimension of the gene predicts which clinical outcome, and the answer turned out to be layered: protein overexpression for recurrence, mutation and gene expression for progression. As molecular pathology moves toward routine multi-parametric profiling of tumors, this work is a reminder that the most clinically useful biomarker may not be a single mutation call but a carefully integrated portrait of gene, transcript, and protein. For the thousands of patients diagnosed each year with high-grade T1 bladder cancer, facing the anxious uncertainty of watchful waiting after bladder-sparing therapy, such a portrait could one day mean the difference between confident surveillance and timely, potentially curative intervention.

Subject of Research: FGFR3 molecular profiling as a prognostic marker in high-grade T1 bladder cancer

Article Title: Prognostic impact of FGFR3 molecular profiling in high-grade T1 bladder cancer

Article References: Mercader, C., Ingelmo-Torres, M., Roldán, F. L., Figueras, M., Carrasco, R., Alfambra, H., Carbonell, E., Narváez, P., Ruiz, R., Calderon, R., López, R., Trias, I., Rodríguez-Carunchio, L., Carrasco, J. L., Oriola, J., Alcaraz, A., Vilaseca, A., & Mengual, L. (2026). Prognostic impact of FGFR3 molecular profiling in high-grade T1 bladder cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09036-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09036-7

Keywords: bladder cancer, FGFR3, high-grade T1, non-muscle invasive bladder cancer, protein overexpression, recurrence, progression, prognosis, immunohistochemistry, Sanger sequencing, RT-qPCR, biomarkers